After the legal case – where next for pharma industry transparency?
August 26, 2015Research and Development clinical trial transparency, clinical trials, health research authority, transparency
Even in an industry as litigious as pharma can sometimes be, the recent legal drama that has played out in …
Novo Nordisk abandons Victoza submission after mixed T1D results
August 26, 2015Research and Development Novo Nordisk, Victoza, diabetes, insulin
Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …
Researchers hopeful experimental antiviral treatment stops Ebola
August 26, 2015Research and Development Ebola, Ebola virus, Ebola virus disease, Toyama Chemical, VSV-ZEBOV, favipiravir, zmapp
An experimental antiviral therapy may have prevented British healthcare workers from contracting Ebola after exposure to the disease in West …
Lilly and Boehringer launch biosimilar insulin in the UK
August 26, 2015Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly
Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …
TSRI and Janssen close in on universal flu vaccine
August 25, 2015Manufacturing and Production Janssen, Vaccine, flu, immunology, universal flu vaccine
Scientists from Janssen and The Scripps Research Institute (TSRI) have found a way to induce antibodies to fight a wide …
Allergan recalls eye drugs after complaints of blurred vision
August 25, 2015Manufacturing and Production Allergan, manufacturing, product recalls, production, recalls
Allergan has issued a recall for batches of eye ointments sold in the US, after customers complained of foreign bodies …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
AZ appoints Genentech’s Sean Bohen as chief medical officer
August 25, 2015Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Briggs Morrison, Sean Bohen
AstraZeneca has appointed Dr Sean Bohen as executive vice president of global medicines development and chief medical officer.Dr Bohen will …
Clinical Trial Transparency – A Personal View
August 24, 2015Research and Development ABPI, PMCPA, clinical trial transparency, clinical trials, health research authority, transparency
During the time I worked as research, medical and innovation director at the ABPI, between October 2012 and January 2015, …
AstraZeneca cancer drug trialled for pancreatic cancer
August 24, 2015Research and Development
AstraZeneca is working with the Banner MD Anderson Cancer Center in Arizona to test its cancer drug Lynparza as a …
AstraZeneca and Peregrine in immuno-oncology collaboration
August 24, 2015Research and Development AstraZeneca, Cancer, MEDI4736, Peregrine, Peregrine Pharmaceuticals, bavituximab, durvalumab, immunoncology, immunotherapy, oncology, tumours
AstraZeneca and Peregrine Pharmaceuticals will collaborate on a clinical trial to test two of the companies’ cancer treatments. The Phase …
Doctors ‘face jail over pharma payments’
August 24, 2015Sales and Marketing ABPI, Jeremy Hunt, NHS, PMCPA, bribery, doctor payments, health secretary, transparency
Healthcare professionals who have inappropriate financial links with pharma companies will face prosecution and up to 10 years in jail, …
Takeda gets European MAA approval for ixazomib
August 21, 2015Medical Communications, Research and Development (FDA/EMA/MHRA), FDA/EMA/MHRA, Takeda, ixazomib, multiple myeloma
Takeda has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for ixazomib, an investigational …
Novartis buys rights to GSK MS drug for up to $1 billion
August 21, 2015Medical Communications, Research and Development, Sales and Marketing GlaxoSmithKline, Novartis, multiple sclerosis, ofatumumab
Novartis has added to its burgeoning multiple sclerosis portfolio with the $300 million acquisition of all outstanding rights to GlaxoSmithKline’s …
Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks
August 21, 2015Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs
Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …
Sun Pharma gets FDA approval for acne treatment
August 21, 2015Medical Communications, Research and Development, Sales and Marketing Sun Pharma. acne treatments, drug approvals
The FDA has approved Sun Pharma’s new acne treatment, Ximino.The Ximino (minocycline hydrochloride) extended-release capsules, which will be available in …
Horizon Pharma receives third rejection from Depomed
August 21, 2015Sales and Marketing Depomed, Horizon Pharma, pharma mergers and acquisitions
Depomed has announced that its board has unanimously rejected Horizon Pharma’s third proposal to buy the California-based company. Following its …
Monique Levy joins Google’s healthcare advisory board
August 20, 2015Medical Communications google
Monique Levy, vice president of digital innovation at healthcare data and analytics firm Decision Resources Group, is joining Google’s healthcare …
FDA hits Mylan’s Indian plants with warning letter
August 20, 2015Manufacturing and Production Contamination, FDA, Mylan, Pfizer, manufacturing, production
The FDA has served Mylan with a warning letter citing contamination at three of its manufacturing facilities in India. Inspections …
Novartis and Merck skin cancer drugs move through pipeline
August 20, 2015Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib
Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
